Collagen Solutions PLC Collagen Based Spray Adhesive Poster Presented
10 Abril 2017 - 1:00AM
RNS Non-Regulatory
TIDMCOS
Collagen Solutions PLC
10 April 2017
Collagen Solutions Plc
(the "Company" or the "Group")
POSTER PRESENTED AT SOCIETY FOR BIOMATERIALS ANNUAL MEETING
Collagen-Based Spray Adhesive Shows Promising Data for Wound
Care Applications
Collagen Solutions plc (AIM: COS), the developer and
manufacturer of medical grade collagen components for use in
regenerative medicine, medical devices and in-vitro diagnostics,
presented a poster at the Society for Biomaterials (SFB) Annual
Meeting in Minneapolis, under the category "Active Wound Dressings
for Advanced Wound Care", highlighting new data related to a wound
healing project from their fibrillar collagen development
programme.
The conference ran from April 5-8 and draws clinicians,
researchers, and medical device manufactures from around the world
to present innovative research, introduce new technologies, and
encourage collaborations for the translation of academic research
to clinical practice. At the meeting, scientists from the Company
presented a poster titled 'Evaluation of Fibroblast Behavior on a
Collagen-Based Spray Adhesive' (#507), which expands on the
Company's investigation into the potential for a fibrillar
collagen-based spray that protects autologous cells during delivery
and promotes cellular adhesion to a wound site.
The long-term potential of the research may address the
limitations of current split or full-thickness autologous skin
grafts, particularly in large wound sites. One of the primary
disadvantages of these procedures is the lack and size of healthy
donor sites that can be used; however, a much smaller amount of
donor skin is required when autologous cells are harvested and
expanded ex-vivo prior to being delivered to the wound.
Commenting on the presentation, Jamal Rushdy, CEO of Collagen
Solutions said: "The expansion of this research project and the
presentation of additional data in Minneapolis shows continued
promise for the possible applications of our fibrillar collagen,
and is part of our broader strategy to develop innovative finished
devices. In particular, this novel mechanism for autologous cell
delivery via a fibrillar collagen-based spray has the potential to
address current shortcomings of products that serve the $3.8 Bn
global regenerative wound healing market."
Additional meeting details can be accessed on the conference
website and the poster can be viewed on the Company's website
here.
About Collagen Solutions:
Collagen Solutions Plc is a global supplier, developer, and
manufacturer of medical grade collagen, tissues, and related
medical devices and components for use in regenerative medicine,
medical devices and in-vitro diagnostics and research. The Company
is also expanding its range of biomaterials-based finished medical
devices based on its internal and acquired intellectual property
for commercialisation with partners via licensing and distribution
arrangements, including ChondroMimetic, an osteochondral scaffold
for repairing cartilage defects in the knee. The Company's products
are used in a wide variety of applications including orthopedics,
cardiovascular, dental, plastic surgery, wound healing, neurology
and urology.
For more information, visit www.collagensolutions.com
Enquiries:
Collagen Solutions Plc Contact via Walbrook
Jamal Rushdy, Chief Executive
Officer
Gill Black, Chief Financial
Officer
Cenkos Securities plc (Nominated Tel: 0207 397 8900
Adviser and Broker)
Stephen Keys
Steve Cox
Walbrook PR Tel: 020 7933 8780 or collagen@walbrookpr.com
Mike Wort Mob: 07900 608 002
Anna Dunphy Mob: 07876 741 001
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAOKODBFBKDKQK
(END) Dow Jones Newswires
April 10, 2017 02:00 ET (06:00 GMT)
Healthcare Inv (LSE:HIO)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025
Healthcare Inv (LSE:HIO)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025
